Search BDSX
BIODESIX INC
Nasdaq · CIK 1439725
Last close27.72
Daily change+0.39 (1.43%)
10 Years gain-89.18%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
BDSX · STANDARD
SIC 8071 · Services-Medical Laboratories · Fiscal year end 1231
Fundamental
68.8Momentum
100.0Acceleration
100.0Confidence
75.0Annual Revenue7
Quarterly Revenue21
Annual CFO7
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth25.0 / 25
Quality16.4 / 25
Capital Efficiency9.3 / 20
Balance Sheet8.0 / 15
Shareholder Economics10.0 / 10
Forward Indicators0.0 / 5
Signals
Operating leverageOperating margin improved by 23.6122 percentage points.
ROIC expansionROIC improved by 41.7343 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Warnings
Heavy share dilution · HIGHDiluted share count increased 41.0411%.
Low interest coverage · HIGHInterest coverage is -3.5757x.
Key Metrics
Revenue Growth TTM36.82%OK
Revenue CAGR 3Y32.31%OK
Gross Margin100%OK
Operating Margin-30.1%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-55.85%OK
Incremental Operating Margin 3Y36.72%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y41.04%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $88.50M | $88.50M | -$27.87M | -$23.27M | -$23.53M | 100% | -31.5% | -26.59% | -69.67% | 7.55M |
| 2025 FY Dec 31, 2024 | $71.32M | $71.32M | -$34.50M | -$48.65M | -$51.88M | 100% | -48.37% | -72.74% | -102.78% | 6.47M |
| 2024 FY Dec 31, 2023 | $49.09M | $49.09M | -$41.34M | -$22.87M | -$45.79M | 100% | -84.22% | -93.28% | -251.05% | 82.11M |
| 2023 FY Dec 31, 2022 | $38.21M | $38.21M | -$50.59M | -$44.97M | -$48.27M | 100% | -132.39% | -126.32% | -1,688.01% | 42.1M |
| 2022 FY Dec 31, 2021 | $54.51M | $54.51M | -$40.94M | -$28.22M | -$30.46M | 100% | -75.11% | -55.89% | n/a | 27.37M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $94.20M | sum latest 4 fiscal quarters Revenue | OK | 0001193125-26-335036, 0001193125-25-262532 |
| Revenue Growth TTM | 36.82% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001193125-26-335036, 0001193125-25-262532 |
| Revenue CAGR 3Y | 32.31% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-076547 |
| Revenue CAGR 5Y | 14.2% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001193125-26-076547 |
| Gross Profit CAGR 3Y | 32.31% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-076547 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001193125-26-335036, 0001193125-25-262532 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 100% | Gross Profit / Revenue | OK | 0001193125-26-335036, 0001193125-25-262532 |
| Operating Margin | -30.1% | Operating Income / Revenue | OK | 0001193125-26-335036, 0001193125-25-262532 |
| ROIC | -55.85% | NOPAT / Average Invested Capital | OK | 0001193125-26-335036, 0001193125-25-262532 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001193125-26-335036 |
| Interest Coverage | -3.58x | Operating Income / abs(Interest Expense) | OK | derived |
| Current Ratio | 2.85x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 0.6x | (Cash + Short-term Investments) / Total Debt | OK | 0001193125-26-335036 |